AstraZeneca Canada Inc.

37 articles about AstraZeneca Canada Inc.

• Breast Cancer Canada, AstraZeneca Canada and Illumina Join Forces To Launch Breast Cancer Screening and Detection Grants

  6/15/2023

  Breast Cancer Canada announced a new research grant in collaboration with AstraZeneca Canada, a global, science-led biopharmaceutical company and Illumina, a global leader in DNA sequencing and array-based technologies.

• ASTRAZENECA CANADA WINS TWO PRESTIGIOUS CANADIAN HR AWARDS

  9/26/2022

  AstraZeneca Canada, a leading innovation-driven biopharmaceutical company, is proud to announce that it received The Venngo Award for Best Workplace Culture and The LifeWorks Award for Excellence for Financial, Physical & Mental Wellness at the 9th annual Canadian HR Awards, which celebrates the best of the best in human resources across all industries.

• AstraZeneca to supply Canada with 100,000 doses of Evusheld, a long-acting antibody combination for the prevention of COVID-19

  2/23/2022

  AstraZeneca Canada has signed an agreement with the Government of Canada for the supply of 100,000 doses of Evusheld (tixagevimab co-packaged with cilgavimab), its long-acting antibody (LAAB) combination for the prevention (pre-exposure prophylaxis) of COVID-19 in those patient populations who require additional protection. 

• AstraZeneca supports the growth of the C3i Lymphoma Registry, a project led by Dr. Isabelle Fleury at Hôpital Maisonneuve-Rosemont

  12/16/2021

  The C3i Center (C3i) is proud to announce the participation of AstraZeneca Canada (AstraZeneca) in supporting the development of the Lymphoma Registry.

• AstraZeneca Canada Named a Greater Toronto Top Employer for Eighth Straight Year

  12/3/2021

  AstraZeneca Canada, a leading innovation-driven biopharmaceutical company, has been selected for the eighth consecutive year as one of Greater Toronto's Top Employers.

• AstraZeneca Canada Files for Health Canada Authorization of AZD7442 for Prevention Of COVID-19

  11/3/2021

  AstraZeneca Canada has initiated a rolling review New Drug Submission with Health Canada for authorization of AZD7442, its long-acting antibody combination, for prevention of symptomatic COVID-19.

• Canadian Oncology Community Unites For World Cancer Day: Shedding Light on the Impact of Covid-19 on Cancer Care

  2/4/2021

  Just over one year since the first case of COVID-19 was reported in Canada, new data now reveals the far-reaching impact of the pandemic on cancer care.

• New Treatment Approved in Canada for Most Common Type of Leukemia

  1/8/2020

  CALQUENCE® (acalabrutinib) is now available for adult patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia

• Information Update - Health Canada update on the tamoxifen shortage

  11/20/2019

  Health Canada is providing Canadians with an update on the supply of tamoxifen, a breast cancer drug, and information on efforts to resolve the national shortage as quickly as possible, recognizing the potentially significant impact that the shortage could have on patients.

• Health Canada approves CALQUENCE (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma (MCL)

  10/8/2019

  AstraZeneca Canada today announced the Health Canada approval of Calquence® (acalabrutinib) as an oral therapy for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

• Symbicort® Turbuhaler® now approved by Health Canada for use in mild persistent, moderate, or severe asthma

  9/30/2019

  AstraZeneca Canada announced that Health Canada has approved the expanded use of Symbicort® Turbuhaler® for the treatment of mild persistent asthma in patients 12 years and older.

• First and Only PARP Inhibitor, Lynparza® (Olaparib) Approved as a First-line Maintenance Therapy Treatment in BRCA-Mutated Advanced Ovarian Cancer - May 8, 2019

  5/8/2019

  AstraZeneca and Merck's Lynparza reduced the risk of disease progression or death by 70% compared to placebo following response to platinum-based chemotherapy

• First and Only Parp Inhibitor, Lynparza (Olaparib) Approved as a First-line Maintenance Therapy Treatment in BRCA-Mutated Advanced Ovarian Cancer

  5/8/2019

  AstraZeneca Canada and Merck Canada today announced the Health Canada approval of Lynparza (olaparib) as a monotherapy maintenance treatment of adult patients with advanced BRCA-mutated (BRCAm) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to first-line platinum-based chemotherapy.

• Health Canada Approves Tagrisso® (osimertinib) as First-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer

  7/12/2018

  Pivotal FLAURA study demonstrated 18.9 months median progression-free survival for patients receiving Tagrisso versus 10.2 months compared with earlier generation EGFR tyrosine kinase inhibitors

• Health Canada approves Fasenra for patients with severe eosinophilic asthma

  2/26/2018

  Fasenra's approval means physicians have a new option for severe asthma patients with a distinct phenotype.

• AstraZeneca Canada Release: First-In-Class BRCA-Positive Ovarian Cancer Medicine Lynparza (Olaparib) Receives Positive Pan-Canadian Oncology Drug Review (pCODR) Recommendation For Provincial Reimbursement

  9/21/2017

• AstraZeneca Canada Release: Pan-Canadian Oncology Drug Review Recommendation Supports The Use Of Tagrisso (Osimertinib) As The Standard Of Care For T790M Mutated Non-Small Cell Lung Cancer

  5/8/2017

• AstraZeneca Canada Release: Tagrisso (Osimertinib) Demonstrates Superiority Over Chemotherapy In EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

  12/9/2016

• AstraZeneca Canada Release: Lynparza (Olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit For Women With Ovarian Cancer

  11/1/2016

• AstraZeneca Canada Release: Canada Denies Public Access To Potentially Life-Prolonging Ovarian Cancer Treatment LYNPARZA (Olaparib)

  10/5/2016